What podcasts say about Damian Garda
Every statement, with the speaker, the exact quote and the moment it was said.
What Damian Garda has said on podcasts
8 statements · 4 positive · 1 negative · 2 mixed · 1 neutral
Chinese biotech consists of competing firms with diverse strategies and histories.
“the Chinese biotech industry is described as a monolith. But that, of course, is not... how it is. It couldn't be further from the truth. It is rather a bunch of competing firms with differing strategies, differing histories, differing approaches to making medicines for human beings.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 2:18
China’s biotech and scientific rise is highly important to global health’s future.
“The remarkable ascendance of not just the Chinese biotech industry, but the Chinese scientific apparatus, whether it's in academia or industry, is massively important to everything we cover and to the future of global health.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 2:57
B1 Medicines ranks first in the China biotech powerhouse index.
“It is B1 Medicines, formerly Baijin, I believe is how it was pronounced, which is an interesting firm in that they were designed to straddle East and West.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 4:28
B1 Medicines and Hungry Pharmaceuticals each have approximately $50 billion market capitalizations.
“each has a market cap of about $50 billion.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 5:12
The outcomes of B1 Medicines’ and Hungry Pharmaceuticals’ strategies remain uncertain.
“we'll see which of those strategies plays out.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 5:28
The proposed Treasury rule appears to exempt conventional drug-licensing deals with Chinese companies.
“the proposed rule as written appears to carve out the kind of deals we seem to see once a week where the likes of Pfizer or Bristol-Myers Squibb or Merck licenses a medicine from a Chinese company.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 7:17
The proposed rule would harm America’s venture-capital community by restricting complex China biotech deals.
“what would be affected is something that would be much more deleterious to america's venture capital community which is more complicated deals”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 7:31
The proposed Treasury rule may change substantially or never be implemented.
“American firms taking equity in Chinese firms. This will all get ironed out. And as with any proposed rule change, if implemented, it could be quite different. It could also never be implemented.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 7:56
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.